Document is current
Any future updates will be listed below
-
Authors
Matsue, Kosei http://orcid.org/0000-0002-8669-9865
Sunami, Kazutaka
Matsumoto, Morio
Kuroda, Junya
Sugiura, Isamu
Iwasaki, Hiromi
Chung, Weiyuan
Kuwayama, Shigeki
Nishio, Mitsufumi
Lee, Kim
Iida, Shinsuke
-
Funding
Funding for this research was provided by:
Bristol-Myers Squibb
- License Information
-
More Information
Article History
Received: 15 December 2021
Revised: 25 March 2022
Accepted: 27 March 2022
First Online: 16 April 2022
Declarations
:
: K. Matsue reported receiving travel funding from Celgene, a Bristol-Myers Squibb Company, and Janssen. K. Sunami reported honoraria and research funding from AbbVie, Alexion Pharma, Amgen Astellas, Bristol Myers Squibb, Celgene, a Bristol-Myers Squibb Company, Daiichi Sankyo, GlaxoSmithKline, Janssen, MSD, Novartis, Ono, Sanofi, and Takeda. M. Matsumoto reported honoraria from Janssen and Sanofi KK. J. Kuroda reported honoraria and research funding from AbbVie, Bristol Myers Squibb, Celgene, a Bristol-Myers Squibb Company, Chugai, Dainippon Sumitomo, Eizai, Janssen, Kyowa, Nippon Shinyaku, Ono, Otsuka, Sanofi, Sysmex, and Takeda. I. Sugiura reported no competing interests. H. Iwasaki reported research funding from Kyowa Kirin. W. Chung is an employee of Bristol Myers Squibb and has equity ownership in Bristol Myers Squibb. S. Kuwayama is an employee of Bristol Myers Squibb and has equity ownership in Bristol Myers Squibb. M. Nishio is an employee of Bristol Myers Squibb and has equity ownership in Bristol Myers Squibb. K. Lee is an employee of Bristol Myers Squibb and has equity ownership in Bristol Myers Squibb. S. Iida received honoraria and research funding from Celgene, a Bristol-Myers Squibb Company, Janssen, Takeda, Ono, Sanofi, and Daiichi Sankyo and research funding from Chugai, Bristol Myers Squibb, AbbVie, Kyowa Kirin, and GlaxoSmithKline.
